Trial Profile
An explosive study on add-on effects of ribavirin in sofosbuir and ledipasvir combination therapy for patients who failed to daclatasvir and asunaprevir combination therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jun 2020
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 03 Jun 2020 Status changed from active, no longer recruiting to completed.
- 29 Sep 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 24 Dec 2015 New trial record